Biogen Inc (BIIB)
Biogen Inc (BIIB) carries a ŷRobot AI score of 64 out of 100. The model's fair value estimate is $237.90, 2.3% above the last close of $232.65. The chart signal reads Sell.
| Metric | BIIB |
|---|---|
| AI score | 64 / 100 |
| Chart signal | Sell |
| Fair value estimate | $237.90 |
| Upside to fair value | 2.3% |
| Previous close | $232.65 |
| P/E | 40.19 |
| Price / sales | 3.28 |
| Market cap | $34.40B |
| EPS | 5.62 |
| Revenue growth | -1.3% |
| 1-year price change | -2.7% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, UnitedHealth Group Incorporated, Merck & Company Inc, Novartis AG ADR.
Questions about BIIB
Is BIIB overvalued or undervalued right now?
As of Oct 16, 2026, ŷRobot's fair-value model estimates Biogen Inc (BIIB) at $237.90 against a last close of $232.65, implying 2.3% upside to the model's estimate.
Is BIIB's chart signal bullish or bearish?
The chart-signal model classifies BIIB as Neutral as of Oct 16, 2026, with a signal score of -0.13 on a -1 to 1 scale.
What is BIIB's ŷRobot AI score?
BIIB scores 64 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Oct 16, 2026.
Is BIIB stock expensive on P/E and P/S?
BIIB trades at 40.2 times earnings and 3.3 times sales as of Oct 16, 2026.
What does BIIB's seasonal forecast show?
ŷRobot's seasonal forecast curve for BIIB reads +0.3% at 30 days, +2.5% at 90 days, and -2.7% at one year as of Oct 16, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is BIIB growing?
Biogen Inc's revenue growth is -1.3% and free-cash-flow growth is -5.9% on the latest reported figures.
BIIB chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.